HK1210416A1 - Bioerodible silicon-based devices for delivery of therapeutic agents - Google Patents
Bioerodible silicon-based devices for delivery of therapeutic agentsInfo
- Publication number
- HK1210416A1 HK1210416A1 HK15111163.1A HK15111163A HK1210416A1 HK 1210416 A1 HK1210416 A1 HK 1210416A1 HK 15111163 A HK15111163 A HK 15111163A HK 1210416 A1 HK1210416 A1 HK 1210416A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- delivery
- therapeutic agents
- based devices
- bioerodible
- silicon
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/025—Other specific inorganic materials not covered by A61L27/04 - A61L27/12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40893410P | 2010-11-01 | 2010-11-01 | |
US201161470299P | 2011-03-31 | 2011-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1210416A1 true HK1210416A1 (en) | 2016-04-22 |
Family
ID=46024803
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15110964.4A HK1210048A1 (en) | 2010-11-01 | 2015-11-06 | Bioerodible silicon-based devices for delivery of therapeutic agents |
HK15111163.1A HK1210416A1 (en) | 2010-11-01 | 2015-11-12 | Bioerodible silicon-based devices for delivery of therapeutic agents |
HK15111162.2A HK1210415A1 (en) | 2010-11-01 | 2015-11-12 | Bioerodible silicon-based devices for delivery of therapeutic agents |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15110964.4A HK1210048A1 (en) | 2010-11-01 | 2015-11-06 | Bioerodible silicon-based devices for delivery of therapeutic agents |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15111162.2A HK1210415A1 (en) | 2010-11-01 | 2015-11-12 | Bioerodible silicon-based devices for delivery of therapeutic agents |
Country Status (11)
Country | Link |
---|---|
US (3) | US9333173B2 (xx) |
EP (1) | EP2635255B1 (xx) |
JP (2) | JP6026424B2 (xx) |
CN (4) | CN104586742A (xx) |
AU (2) | AU2011323524B2 (xx) |
CA (1) | CA2816576C (xx) |
HK (3) | HK1210048A1 (xx) |
IN (1) | IN2013MN00758A (xx) |
RU (1) | RU2640918C2 (xx) |
TW (1) | TWI615150B (xx) |
WO (1) | WO2012061377A1 (xx) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9808052D0 (en) | 1998-04-17 | 1998-06-17 | Secr Defence | Implants for administering substances and methods of producing implants |
JP5858906B2 (ja) | 2009-05-04 | 2016-02-10 | シヴィダ・ユーエス・インコーポレイテッドPsivida Us, Inc. | 多孔質シリコン薬物溶出粒子 |
JP6026424B2 (ja) | 2010-11-01 | 2016-11-16 | シヴィダ・ユーエス・インコーポレイテッドPsivida Us, Inc. | 治療薬送達のための生物浸食性ケイ素ベースのデバイス |
US20140309610A1 (en) * | 2013-03-12 | 2014-10-16 | Psivida Corp. | Drug Delivery Device Comprising Silicon-Based Carrier Particles |
WO2014165108A1 (en) * | 2013-03-12 | 2014-10-09 | Psivida Us, Inc. | Bioerodible silicon-based delivery vehicles for delivery of therapeutic agents |
AU2014235051B2 (en) * | 2013-03-15 | 2019-01-17 | Eyepoint Pharmaceuticals Us, Inc. | Bioerodible silicon-based compositions for delivery of therapeutic agents |
WO2016044366A1 (en) * | 2014-09-16 | 2016-03-24 | Psivida Us, Inc. | Compositions and methods for controlled release of agents |
JP6883257B2 (ja) * | 2017-05-16 | 2021-06-09 | 株式会社豊田中央研究所 | 還元反応用固体触媒 |
WO2019246130A1 (en) | 2018-06-19 | 2019-12-26 | Cella Therapeutics, Llc | Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension |
AU2019290582A1 (en) | 2018-06-19 | 2021-01-28 | Cella Therapeutics, Llc | Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS ligand (FASL) inhibitor, a tumor necrosis factor-alpha (TNF-alpha) or TNF receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease |
TWI803092B (zh) * | 2021-04-01 | 2023-05-21 | 逢甲大學 | 具負載與釋放活性成分的奈米粒子、其製造方法與眼用裝置之應用 |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3832458A (en) | 1971-12-06 | 1974-08-27 | River C Foundation | Hydrophilic silicone composition and method |
US4036979A (en) | 1974-01-25 | 1977-07-19 | American Cyanamid Company | Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate |
US3919723A (en) | 1974-05-20 | 1975-11-18 | Friedrichsfeld Gmbh | Bone shaft or bone joint prosthesis and process |
US3919060A (en) | 1974-06-14 | 1975-11-11 | Ibm | Method of fabricating semiconductor device embodying dielectric isolation |
DE3214667C2 (de) | 1982-04-21 | 1985-07-18 | Akzo Gmbh, 5600 Wuppertal | Zusammengesetzter Körper für die Langzeitabgabe von Wirkstoffen |
JPS59101145A (ja) | 1982-11-30 | 1984-06-11 | 日本特殊陶業株式会社 | 薬液含浸多孔質セラミツクス |
JPS59131346A (ja) | 1983-01-17 | 1984-07-28 | 日本特殊陶業株式会社 | 薬液含浸多孔質セラミツクスの製造法 |
DE3423667A1 (de) | 1984-05-08 | 1985-11-28 | Rüdiger Dipl.-Ing. 5204 Lohmar Scheunemann | Implantat fuer knochen- und zahnwurzelersatz mit spezieller uebergangsstruktur zwischen knochen und implantatkern und knochenseitig ganz oder teilweise resorbierbarer matrix |
GB8422876D0 (en) | 1984-09-11 | 1984-10-17 | Secr Defence | Silicon implant devices |
US4608048A (en) | 1984-12-06 | 1986-08-26 | Alza Corporation | Dispensing device with drug delivery patterns |
US5057082A (en) | 1988-11-04 | 1991-10-15 | Plastic Injectors, Inc. | Trocar assembly |
DK0463061T3 (da) | 1989-03-17 | 1993-07-12 | Pitman Moore Inc | Controlled-release tilførselsindretning til afgivelse af makromolekylære proteiner |
US5167625A (en) | 1990-10-09 | 1992-12-01 | Sarcos Group | Multiple vesicle implantable drug delivery system |
NZ247392A (en) * | 1992-04-30 | 1995-05-26 | Takeda Chemical Industries Ltd | Prefilled syringe containing two substances mixed before injection |
US5366454A (en) | 1993-03-17 | 1994-11-22 | La Corporation De L'ecole Polytechnique | Implantable medication dispensing device |
US5370630A (en) | 1993-11-12 | 1994-12-06 | Smidebush; Michael J. | Device for injection of fluidic materials into body tissue |
US5489266A (en) * | 1994-01-25 | 1996-02-06 | Becton, Dickinson And Company | Syringe assembly and method for lyophilizing and reconstituting injectable medication |
US5558071A (en) | 1994-03-07 | 1996-09-24 | Combustion Electromagnetics, Inc. | Ignition system power converter and controller |
US5591453A (en) | 1994-07-27 | 1997-01-07 | The Trustees Of The University Of Pennsylvania | Incorporation of biologically active molecules into bioactive glasses |
US5817327A (en) | 1994-07-27 | 1998-10-06 | The Trustees Of The University Of Pennsylvania | Incorporation of biologically active molecules into bioactive glasses |
US5665114A (en) | 1994-08-12 | 1997-09-09 | Meadox Medicals, Inc. | Tubular expanded polytetrafluoroethylene implantable prostheses |
US5792099A (en) | 1995-02-14 | 1998-08-11 | Decamp; Dennis | Syringe and cannula for insertion of viscoelastic material into an eye and method of using same |
MX9707585A (es) | 1995-04-03 | 1997-12-31 | Abbott Lab | Mezclas homogeneas de farmacos y aditivos de fusion a baja temperatura para liberacion controlada. |
US6096344A (en) | 1995-07-28 | 2000-08-01 | Advanced Polymer Systems, Inc. | Bioerodible porous compositions |
GB9611437D0 (en) | 1995-08-03 | 1996-08-07 | Secr Defence | Biomaterial |
US5665428A (en) | 1995-10-25 | 1997-09-09 | Macromed, Inc. | Preparation of peptide containing biodegradable microspheres by melt process |
DE19608423A1 (de) | 1996-03-05 | 1997-09-11 | Merck Patent Gmbh | Implantate mit phasenweiser Arzneistoffabgabe |
FR2749169B1 (fr) * | 1996-06-04 | 1998-08-21 | Delab | Procede pour constituer une preparation injectable et dispositif pour la mise en oeuvre de ce procede |
US7070590B1 (en) | 1996-07-02 | 2006-07-04 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
US5797898A (en) | 1996-07-02 | 1998-08-25 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
US5922299A (en) | 1996-11-26 | 1999-07-13 | Battelle Memorial Institute | Mesoporous-silica films, fibers, and powders by evaporation |
JP3217286B2 (ja) * | 1996-12-19 | 2001-10-09 | 科学技術振興事業団 | Dna固定化複合体 |
AU2460099A (en) | 1998-01-20 | 1999-08-02 | Drexel University | Mesoporous materials and methods of making the same |
US6696258B1 (en) | 1998-01-20 | 2004-02-24 | Drexel University | Mesoporous materials and methods of making the same |
US6060036A (en) | 1998-02-09 | 2000-05-09 | Implant Sciences Corporation | Radioactive seed implants |
GB9808052D0 (en) | 1998-04-17 | 1998-06-17 | Secr Defence | Implants for administering substances and methods of producing implants |
GB9815819D0 (en) | 1998-07-22 | 1998-09-16 | Secr Defence | Transferring materials into cells and a microneedle array |
ATE306250T1 (de) | 1998-12-23 | 2005-10-15 | Alza Corp | Dosierungsformen, die poröse partikel enthalten |
EP1154691A4 (en) * | 1999-01-05 | 2004-07-07 | Massachusetts Eye & Ear Infirm | TARGETED ADMINISTRATION OF REGULATED RELEASE MEDICINE TO RETINA AND CHOROID THROUGH SCLEROTIC |
AU7881000A (en) * | 1999-08-16 | 2001-03-13 | Henceforth Hibernia, Inc. | Therapeutic and prophylactic compositions including catalytic biomimetic solids and methods to prepare and use them |
GB9924334D0 (en) | 1999-10-15 | 1999-12-15 | Secr Defence | Pharmaceutical products and methods of fabrication therefor |
ES2182731T1 (es) | 1999-10-18 | 2003-03-16 | Ferx Inc | Vehiculo magnetico para dirigir un agente biologicamente activo a un sitio especifico. |
SE9903958D0 (sv) | 1999-11-02 | 1999-11-02 | Boerje Sellergren | Porous materials for selective binding or transport of molecular guests |
US6521284B1 (en) | 1999-11-03 | 2003-02-18 | Scimed Life Systems, Inc. | Process for impregnating a porous material with a cross-linkable composition |
AUPQ573300A0 (en) | 2000-02-21 | 2000-03-16 | Australian Nuclear Science & Technology Organisation | Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use |
DE60124387T2 (de) | 2000-02-28 | 2007-10-11 | Pfizer Enterprises Sarl. | Synergistische pharmazeutische Zusammensetzungen zur Behandlung von kolorektalem Krebs |
IL134830A0 (en) | 2000-03-01 | 2001-05-20 | Chay 13 Medical Res Group N V | Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them |
KR20030009389A (ko) | 2000-03-14 | 2003-01-29 | 브루카드 괴케 | 유문동-유문-십이지장 운동성에 대한 글루카곤 유사펩티드-1 (7-36)의 효과 |
GB0008494D0 (en) | 2000-04-07 | 2000-05-24 | Secr Defence | Microprojectile delivery system |
GB2365769A (en) | 2000-08-18 | 2002-02-27 | Secr Defence | Skin preparations containing silicon |
GB0104383D0 (en) | 2001-02-22 | 2001-04-11 | Psimedica Ltd | Cancer Treatment |
US6973718B2 (en) | 2001-05-30 | 2005-12-13 | Microchips, Inc. | Methods for conformal coating and sealing microchip reservoir devices |
CA2496736C (en) | 2002-08-23 | 2012-11-13 | Mcmaster University | Methods and compounds for controlling the morphology and shrinkage of silica derived from polyol-modified silanes |
PL223153B1 (pl) | 2002-09-18 | 2016-10-31 | Allergan Inc | Urządzenie do wszczepiania implantu okulistycznego |
WO2004071949A2 (en) | 2003-02-13 | 2004-08-26 | The Regents Of The University Of California | Nanostructured casting of organic and bio-polymers in porous silicon templates |
US7433811B2 (en) | 2003-05-06 | 2008-10-07 | The Regents Of The University Of California | Direct patterning of silicon by photoelectrochemical etching |
US7563451B2 (en) | 2003-07-22 | 2009-07-21 | Iowa State University Research Foundation, Inc. | Capped mesoporous silicates |
GB0324483D0 (en) * | 2003-10-21 | 2003-11-19 | Psi Medica Ltd | Composite material |
WO2005042023A1 (en) | 2003-10-21 | 2005-05-12 | Psimedica Limited | Composite material comprising a porous semiconductor impregnated with an organic substance |
US20050181049A1 (en) | 2003-11-19 | 2005-08-18 | Dong Liang C. | Composition and method for enhancing bioavailability |
US7448867B2 (en) | 2004-09-17 | 2008-11-11 | Ormco Corporation | Medical treatment apparatus |
US20060067979A1 (en) | 2004-09-30 | 2006-03-30 | Bausch & Lomb Incorporated | Ophthalmic drug release device for multiple drug release |
WO2006037160A1 (en) * | 2004-10-05 | 2006-04-13 | The University Of Melbourne | Porous polyelectrolyte materials |
US20090208556A1 (en) | 2004-10-29 | 2009-08-20 | Regents Of The University Of California, The | Porous photonic crystals for drug delivery to the eye |
WO2006067979A1 (ja) | 2004-12-21 | 2006-06-29 | Nec Corporation | フィルム外装電気デバイス用ケース |
JP2007091716A (ja) | 2005-08-29 | 2007-04-12 | Kuraray Co Ltd | 水中薬剤徐放性微粒子及びその製造方法 |
GB0526332D0 (en) | 2005-12-23 | 2006-02-01 | Psimedica Ltd | Pharmaceutical product |
US8119394B2 (en) * | 2006-03-14 | 2012-02-21 | University Of Rochester | Cell culture devices having ultrathin porous membrane and uses thereof |
BRPI0709672B8 (pt) | 2006-03-31 | 2021-06-22 | 3088922 Inc | implante ocular insersível em um lúmen ocular e método de distribuição de um agente terapêutico a um olho |
JP4984644B2 (ja) * | 2006-05-19 | 2012-07-25 | 株式会社ジェイ・エム・エス | 注射装置 |
US20080057102A1 (en) | 2006-08-21 | 2008-03-06 | Wouter Roorda | Methods of manufacturing medical devices for controlled drug release |
CN101541836B (zh) | 2006-09-25 | 2015-04-08 | 阿彻-丹尼尔斯-米德兰德公司 | 超吸收性的经表面处理的羧烷基化多糖及其制备方法 |
JP5141948B2 (ja) * | 2007-07-09 | 2013-02-13 | 株式会社豊田中央研究所 | バイモダルな細孔構造を有する球状シリカ系メソ多孔体及びその製造方法 |
AU2008275181B2 (en) | 2007-07-10 | 2014-06-26 | The Regents Of The University Of California | Materials and methods for delivering compositions to selected tissues |
US20130084243A1 (en) | 2010-01-27 | 2013-04-04 | Liliane Goetsch | Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders |
CA2735899A1 (en) | 2008-09-25 | 2010-04-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
GB0817936D0 (en) * | 2008-09-30 | 2008-11-05 | Intrinsiq Materials Global Ltd | Porous materials |
GB0817938D0 (en) | 2008-09-30 | 2008-11-05 | Intrinsiq Materials Global Ltd | Cosmetic formulations |
JP5369725B2 (ja) | 2009-01-30 | 2013-12-18 | 株式会社ニコン | 撮像装置 |
WO2010090596A1 (en) * | 2009-02-04 | 2010-08-12 | Agency For Science, Technology And Research | Hollow silica particle with a polymer thereon |
US20110300222A1 (en) | 2009-02-20 | 2011-12-08 | The Regents Of The University Of California | Luminescent porous silicon nanoparticles, methods of making and using same |
WO2010111627A1 (en) | 2009-03-26 | 2010-09-30 | Psivida Us, Inc. | Implantable formulations of bisphosphonic acids |
JP5382700B2 (ja) | 2009-03-27 | 2014-01-08 | 独立行政法人産業技術総合研究所 | ロッド状多孔質シリカ粒子 |
JP5858906B2 (ja) | 2009-05-04 | 2016-02-10 | シヴィダ・ユーエス・インコーポレイテッドPsivida Us, Inc. | 多孔質シリコン薬物溶出粒子 |
US20110028412A1 (en) | 2009-08-03 | 2011-02-03 | Cappellos, Inc. | Herbal enhanced analgesic formulations |
DE102010008982A1 (de) | 2010-02-24 | 2011-08-25 | Bayer Innovation GmbH, 40225 | Siliciumhaltiges, biologisch degradierbares Material zur anti-inflammatorischen Therapie |
GB201017048D0 (en) | 2010-10-08 | 2010-11-24 | Ucl Business Plc | Composition |
JP6026424B2 (ja) | 2010-11-01 | 2016-11-16 | シヴィダ・ユーエス・インコーポレイテッドPsivida Us, Inc. | 治療薬送達のための生物浸食性ケイ素ベースのデバイス |
WO2012088306A2 (en) | 2010-12-22 | 2012-06-28 | Psivida Us, Inc. | Two-piece injectable drug delivery device with heat-cured seal |
RU2013138180A (ru) | 2011-02-11 | 2015-03-20 | Псивида Юэс, Инк. | Способы лечения макулярного отека с использованием противоотечных лекарственных средств |
EP2691115A1 (en) | 2011-03-31 | 2014-02-05 | Galderma Research & Development | Compositions comprising a filler product and at least one bioresorbable and biodegradable silica-based material |
JP6100782B2 (ja) | 2011-08-29 | 2017-03-22 | キューエルティー インコーポレイテッド | 緑内障および高眼圧症を治療するための活性剤の徐放送達 |
KR20150085078A (ko) | 2012-11-21 | 2015-07-22 | 아지오스 파마슈티컬스 아이엔씨. | 글루타마제 억제제 및 사용 방법 |
WO2014165108A1 (en) | 2013-03-12 | 2014-10-09 | Psivida Us, Inc. | Bioerodible silicon-based delivery vehicles for delivery of therapeutic agents |
WO2016077632A2 (en) | 2014-11-13 | 2016-05-19 | Buck Institute For Research On Aging | Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications |
-
2011
- 2011-11-01 JP JP2013536924A patent/JP6026424B2/ja not_active Expired - Fee Related
- 2011-11-01 AU AU2011323524A patent/AU2011323524B2/en not_active Ceased
- 2011-11-01 CN CN201410822342.1A patent/CN104586742A/zh active Pending
- 2011-11-01 CN CN201410827969.6A patent/CN104622790A/zh active Pending
- 2011-11-01 EP EP11838672.1A patent/EP2635255B1/en active Active
- 2011-11-01 CA CA2816576A patent/CA2816576C/en active Active
- 2011-11-01 US US13/286,788 patent/US9333173B2/en active Active
- 2011-11-01 WO PCT/US2011/058774 patent/WO2012061377A1/en active Application Filing
- 2011-11-01 IN IN758MUN2013 patent/IN2013MN00758A/en unknown
- 2011-11-01 CN CN201410826616.4A patent/CN104622789A/zh active Pending
- 2011-11-01 RU RU2013119438A patent/RU2640918C2/ru active
- 2011-11-01 CN CN201180056566.0A patent/CN103282020B/zh active Active
- 2011-11-01 TW TW100139841A patent/TWI615150B/zh not_active IP Right Cessation
-
2015
- 2015-11-06 HK HK15110964.4A patent/HK1210048A1/xx unknown
- 2015-11-12 HK HK15111163.1A patent/HK1210416A1/xx unknown
- 2015-11-12 HK HK15111162.2A patent/HK1210415A1/xx unknown
-
2016
- 2016-02-04 JP JP2016019772A patent/JP6189460B2/ja not_active Expired - Fee Related
- 2016-05-05 US US15/147,203 patent/US11026885B2/en active Active
- 2016-10-20 US US15/299,050 patent/US9808421B2/en active Active
- 2016-11-16 AU AU2016259330A patent/AU2016259330B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
JP6026424B2 (ja) | 2016-11-16 |
IN2013MN00758A (xx) | 2015-06-12 |
AU2016259330A1 (en) | 2016-12-08 |
CN104622789A (zh) | 2015-05-20 |
HK1210048A1 (en) | 2016-04-15 |
CN104586742A (zh) | 2015-05-06 |
US20160243276A1 (en) | 2016-08-25 |
CN103282020A (zh) | 2013-09-04 |
JP6189460B2 (ja) | 2017-08-30 |
AU2016259330B2 (en) | 2018-11-08 |
CA2816576C (en) | 2020-06-02 |
CA2816576A1 (en) | 2012-05-10 |
CN103282020B (zh) | 2016-10-26 |
EP2635255B1 (en) | 2019-08-21 |
HK1210415A1 (en) | 2016-04-22 |
US20120177695A1 (en) | 2012-07-12 |
RU2013119438A (ru) | 2014-12-10 |
US20170035690A1 (en) | 2017-02-09 |
US9808421B2 (en) | 2017-11-07 |
JP2013541562A (ja) | 2013-11-14 |
US11026885B2 (en) | 2021-06-08 |
WO2012061377A1 (en) | 2012-05-10 |
JP2016121173A (ja) | 2016-07-07 |
AU2011323524B2 (en) | 2016-12-08 |
EP2635255A1 (en) | 2013-09-11 |
AU2011323524A1 (en) | 2013-05-23 |
TW201306867A (zh) | 2013-02-16 |
TWI615150B (zh) | 2018-02-21 |
CN104622790A (zh) | 2015-05-20 |
EP2635255A4 (en) | 2016-11-09 |
US9333173B2 (en) | 2016-05-10 |
RU2640918C2 (ru) | 2018-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL291554A (en) | Administration of therapeutic agents to the central nervous system | |
HRP20181615T1 (hr) | Terapijsko sredstvo koje izaziva citotoksičnost | |
HK1218719A1 (zh) | 治療試劑的 遞送 | |
HK1210416A1 (en) | Bioerodible silicon-based devices for delivery of therapeutic agents | |
HK1201483A1 (en) | Devices for targeted delivery of therapeutic implants | |
EP2571526A4 (en) | DRUG DELIVERY DEVICES FOR ADMINISTERING OCULAR THERAPEUTIC AGENTS | |
EP2771058A4 (en) | IMPLANTABLE DEVICES FOR ADMINISTERING BIOACTIVE AGENTS | |
HK1216720A1 (zh) | 用於遞送治療劑的可生物蝕解的硅基組合物 | |
ZA201301458B (en) | Therapeutic agent for pain | |
ME02549B (me) | Cns dostava terapeutskih agensa | |
GB201019938D0 (en) | Determination of therapeutic agents | |
GB201014963D0 (en) | Therapeutic agents | |
GB201012101D0 (en) | Therapeutic agents | |
GB201012102D0 (en) | Therapeutic agents | |
GB201012100D0 (en) | Therapeutic agents | |
GB201010582D0 (en) | Therapeutic agents | |
GB201010577D0 (en) | Therapeutic agents | |
GB201010583D0 (en) | Therapeutic agents | |
GB201009614D0 (en) | Therapeutic use of compounds | |
GB201003727D0 (en) | Therapeutic agent |